SCHEMBL4707950

SCHEMBL4707950

CCn1nc(-c2ccccc2)c(C(=O)OC(C)C)c(Nc2cccc(Cl)c2)c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.55
PARP1 P09874 2/20 0.47
ACHE P22303 1/20 0.46
BACE1 P56817 1/20 0.46
SMN1; SMN2 Q16637 6/20 0.45
TP53 P04637 1/20 0.45
PDE4A P27815 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4708343 0.91 PDE4B (0.56) PDE4BPARP1ACHEBACE1SMN1; SMN2
SCHEMBL4707603 0.89 PDE4B (0.55) PDE4BPARP1ACHEBACE1SMN1; SMN2
SCHEMBL4058811 0.89 PDE4B (0.70) PDE4BPARP1ACHEBACE1SMN1; SMN2
SCHEMBL4706084 0.88 PDE4B (0.62) PDE4BPARP1ACHEBACE1SMN1; SMN2
SCHEMBL4708484 0.86 PDE4B (0.52) PDE4BPARP1ACHEBACE1SMN1; SMN2
SCHEMBL4706418 0.86 PDE4B (0.60) PDE4BPARP1ACHEBACE1SMN1; SMN2
SCHEMBL4706645 0.84 PDE4B (0.56) PDE4BPARP1ACHEBACE1SMN1; SMN2
SCHEMBL4707865 0.84 PDE4B (0.62) PDE4BPARP1ACHEBACE1SMN1; SMN2
SCHEMBL4707530 0.83 PDE4B (0.52) PDE4BPARP1ACHEBACE1SMN1; SMN2
SCHEMBL4708001 0.83 PDE4B (0.54) PDE4BPARP1ACHEBACE1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US disclosed
EP-1503992-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2005-02-09 EP disclosed
WO-2003097613-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS ALMIRALL PRODESFARMA SA (ES) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885PARP1 1082/4885ACHE 51/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885PARP1 1082/4885ACHE 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.